Checkpoint inhibition: protecting against or predisposing for second primary tumors?

K P M Suijkerbuijk; A M May; M J M van Eijs

doi:10.1016/j.annonc.2021.03.202

Checkpoint inhibition: protecting against or predisposing for second primary tumors?

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	935-935
Number of pages	1
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	32
Issue number	7
Early online date	29 Mar 2021
DOIs	https://doi.org/10.1016/j.annonc.2021.03.202
Publication status	Published - Jul 2021

Access to Document

10.1016/j.annonc.2021.03.202

1-s2.0-S0923753421010991-mainFinal published version, 96 KBLicence: Taverne

Cite this

@article{d2cdd77f3f5a4a87ab9d1d190d396088,

title = "Checkpoint inhibition: protecting against or predisposing for second primary tumors?",

author = "Suijkerbuijk, \{K P M\} and May, \{A M\} and \{van Eijs\}, \{M J M\}",

note = "Funding Information: None declared. KPMS has advisory relationships with Bristol-Myers Squibb, Novartis, MSD, Pierre Fabre, and AbbVie and received honoraria from Novartis and Roche, all outside the submitted work and paid to institution. All other authors have declared no conflicts of interest.",

year = "2021",

month = jul,

doi = "10.1016/j.annonc.2021.03.202",

language = "English",

volume = "32",

pages = "935--935",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Elsevier Limited",

number = "7",

}

TY - JOUR

T1 - Checkpoint inhibition

T2 - protecting against or predisposing for second primary tumors?

AU - Suijkerbuijk, K P M

AU - May, A M

AU - van Eijs, M J M

N1 - Funding Information: None declared. KPMS has advisory relationships with Bristol-Myers Squibb, Novartis, MSD, Pierre Fabre, and AbbVie and received honoraria from Novartis and Roche, all outside the submitted work and paid to institution. All other authors have declared no conflicts of interest.

PY - 2021/7

Y1 - 2021/7

UR - https://www.scopus.com/pages/publications/85106583844

U2 - 10.1016/j.annonc.2021.03.202

DO - 10.1016/j.annonc.2021.03.202

M3 - Comment/Letter to the editor

C2 - 33794292

SN - 0923-7534

VL - 32

SP - 935

EP - 935

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

IS - 7

ER -

Checkpoint inhibition: protecting against or predisposing for second primary tumors?

Access to Document

Other files and links

Cite this